Pfizer 3Q Earnings Powered by Oncology, Beat Estimates

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates (Reuters)

The United States’ largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates. The company earned $2.59 billion for the quarter, or 58 cents per share (excluding special items), while analysts had predicted 56 cents per share. Much of the additional profit came from a 26 percent pop in oncology drug sales, which totaled $407 million for the quarter. However, global sales for the period fell 7 percent to $12.64, due to generic competition for Lipitor and other drugs. Wall Street had expected sales of $12.7 billion. Investors in Pfizer now have to ask themselves if they can see momentum continuing at that fervid pace for oncology drugs, and if that will be enough to overcome lagging global sales. If you come up with a good answer, please let us know by commenting below.

Eagle Eye Opener

Recent Posts

Sample Weekday Wrap/Closing Comments

This content is for paid subscribers only. To gain access subscribe to one of our…

2 months ago

Soft Landing Premise Still Driving Bullish Narrative

It is hard to find a seasoned investor who doesn’t believe the stock market is…

6 months ago

Are You Prepared for the Next Market Collapse?

No one believes a financial disaster can strike… until it’s too late. That’s bizarre, considering…

1 year ago

Options Industry Council (OIC) – What is It?

The Options Industry Council is a resource used to educate investors about the benefits and…

1 year ago

Put-Call Parity – Defined and Simplified

The put-call parity is the relationship that exists between put and call prices of the…

1 year ago

Three Cheers for the Magnificent Seven

“It’s not a stock market, it’s a market of stocks.” -- “Maxims of Wall Street,”…

1 year ago